Recent Updates
Recently added Catalysts
INO Positive Sentiment Score: 70/100

INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Key Takeaway: INOVIO Pharmaceuticals, Inc. announced that Dr. Jacqueline Shea, the President and CEO, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023. During this event, she will lead a company presentation and hold one-on-one meetings with registered investors to discuss INOVIO's advancements in DNA medicines. The conference is a platform for INOVIO to showcase its efforts in treating HPV-related diseases, cancer, and infectious diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • INOVIO is presenting at a significant investment conference.
  • The event provides opportunities for direct engagement with investors.
  • The company's focus on DNA medicines addresses critical health issues.

Full Press Release Details

PLYMOUTH MEETING, Pa., Aug. 29, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will present at the H.C. Wainwright 25th Annual Global Investment Conference.
H.C. Wainwright 25th Annual Global Investment Conference
Date: Tuesday, September 12, 2023
Format: Company Presentation
During the conference, Dr. Shea and members of INOVIO's management team will conduct one-on-one meetings with registered investors.
A webcast of the presentation will be available on the INOVIO Investor Relations Events page at https://ir.inovio.com/events-and-presentations/default.aspx. A replay of the webcast will be available for 90 days after the date of the presentation.
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's DNA medicines in development are delivered using its investigational proprietary device, CELLECTRA®, to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com.
Media: Jennie Willson (267) 429-8567 [email protected]
Investors: Thomas Hong (267) 440-4298 [email protected]
SOURCE INOVIO Pharmaceuticals, Inc.

21 %

more press release views with

Frequently Asked Questions

What is the focus of INOVIO's development?

INOVIO specializes in DNA medicines for HPV-related diseases, cancer, and infections.

When is the H.C. Wainwright conference presentation?

The presentation will take place on September 12, 2023.

Where can I watch the INOVIO conference presentation?

The presentation will be available on INOVIO's Investor Relations Events page.

What technology does INOVIO use for its DNA medicines?

INOVIO utilizes its proprietary CELLECTRA® device for delivering DNA medicines.

Who is presenting at the upcoming investment conference?

Dr. Jacqueline Shea, President and CEO of INOVIO, will present at the conference.

Last updated: Aug 29, 2023